Glucocorticoids use in kidney transplant setting

References

• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420–426.
   PubMed Web of Science ®Google Scholar
• Strehl C, Spies CM, Buttgereit F. Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011;29:S13–S18.
   PubMed Web of Science ®Google Scholar
• Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60:25–31.
   PubMedGoogle Scholar
• Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61–98.
   PubMed Web of Science ®Google Scholar
• Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells. 2013;2:202–223.
   PubMedGoogle Scholar
• Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203–207.
   PubMedGoogle Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.
   PubMed Web of Science ®Google Scholar
• Smith DJF, Prabhudev H, Choudhury S, et al. Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement. Endocr Connect. 2017;6:766–772.
   PubMed Web of Science ®Google Scholar
• Kemp MW, Newnham JP, Challis JG, et al. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2016;22:240–259.
   PubMed Web of Science ®Google Scholar
• Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55:603–613.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Cidlowski JA. Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev. 2013;24:41–56.
   PubMedGoogle Scholar
• Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163:29–43.
   PubMed Web of Science ®Google Scholar
• Strehl C, Gaber T, Lowenberg M, et al. Origin and functional activity of the membrane-bound glucocorticoid receptor. Arthritis Rheum. 2011;63:3779–3788.
   PubMedGoogle Scholar
• Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78:748–756.
   PubMed Web of Science ®Google Scholar
• Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727–734.
   PubMed Web of Science ®Google Scholar
• Lan NC, Graham B, Bartter FC, et al. Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Metab. 1982;54:332–342.
   PubMed Web of Science ®Google Scholar
• Thiebaud D, Jacot E, DeFronzo RA, et al. The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes. 1982;31:957–963.
   PubMed Web of Science ®Google Scholar
• Fichna M, Fichna P. Glucocorticoids and beta-cell function. Endokrynol Pol. 2017;68:568–573.
   PubMed Web of Science ®Google Scholar
• Ryu JS, Ko JH, Kim MK, et al. Prednisolone induces apoptosis in corneal epithelial cells through the intrinsic pathway. Sci Rep. 2017;7:4135.
   PubMed Web of Science ®Google Scholar
• Chen H, Lombes M, Le MD. Glucocorticoid receptor represses brain-derived neurotrophic factor expression in neuron-like cells. Mol Brain. 2017;10:12.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu Y, Liang Q. Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS. Mol Med Rep. 2018;17:4307–4316.
   PubMed Web of Science ®Google Scholar
• Gao J, Cheng TS, Qin A, et al. Glucocorticoid impairs cell-cell communication by autophagy-mediated degradation of connexin 43 in osteocytes. Oncotarget. 2016;7:26966–26978.
   PubMedGoogle Scholar
• Liu H, Gao X, Xu H, et al. alpha-Actinin-4 is involved in the process by which dexamethasone protects actin cytoskeleton stabilization from adriamycin-induced podocyte injury. Nephrology (Carlton). 2012;17:669–675.
   PubMed Web of Science ®Google Scholar
• Wada T, Pippin JW, Marshall CB, et al. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005;16:2615–2625.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Khoshnoodi J, Takenaka H, et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int. 2006;69:1350–1359.
   PubMed Web of Science ®Google Scholar
• Kiessling S, Beaulieu-Laroche L, Blum ID, et al. Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol. 2017;15:13.
   PubMed Web of Science ®Google Scholar
• Sun YN, McKay LI, Dubois DC, et al. Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther. 1999;288:720–728.
   PubMed Web of Science ®Google Scholar
• Almon RR, Dubois DC, Jin JY, et al. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol. 2005;184:219–232.
   PubMed Web of Science ®Google Scholar
• Almon RR, Dubois DC, Jin JY, et al. Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. Aaps J. 2005;7:E156–E194.
   PubMed Web of Science ®Google Scholar
• Jia J, Yao W, Guan M, et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 2011;25:3366–3376.
   PubMed Web of Science ®Google Scholar
• Zhou H, Tian X, Tufro A, et al. Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury. Sci Rep. 2017;7:9833.
   PubMed Web of Science ®Google Scholar
• Shen X, Jiang H, Ying M, et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep. 2016;6:32087.
   PubMed Web of Science ®Google Scholar
• Qi XM, Wang J, Xu XX, et al. FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats. Inflamm Res. 2016;65:103–114.
   PubMed Web of Science ®Google Scholar
• Fisher LE, Ludwig EA, Wald JA, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm. Clin Pharmacol Ther. 1992;51:677–688.
   PubMed Web of Science ®Google Scholar
• Fisher LE, Ludwig EA, Jusko WJ. Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm. 1992;20:319–331.
   PubMedGoogle Scholar
• Williams EL, Choudhury S, Tan T, et al. Prednisolone replacement therapy mimics the circadian rhythm more closely than otherglucocorticoids. J Appl Lab Med. 2016;1:152–161.
   PubMedGoogle Scholar
• Quinkler M, Ekman B, Marelli C, et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect. 2017;6:1–8.
   PubMed Web of Science ®Google Scholar
• Tufton N, Ahmad S, Rolfe C, et al. New-onset diabetes after renal transplantation. Diabet Med. 2014;31:1284–1292.
   PubMed Web of Science ®Google Scholar
• Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc. 1991;23:3169–3170.
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997;63:977–983.
   PubMed Web of Science ®Google Scholar
• Tillmann FP, Quack I, Schenk A, et al. Prevalence and risk factors of pre-diabetes after renal transplantation: a single-centre cohort study in 200 consecutive patients. Nephrol Dial Transplant. 2012;27:3330–3337.
   PubMed Web of Science ®Google Scholar
• Wauters RP, Cosio FG, Suarez Fernandez ML, et al. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation. 2012;94:377–382.
   PubMed Web of Science ®Google Scholar
• Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75:SS3–24.
   PubMed Web of Science ®Google Scholar
• Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36:2763–2771.
   PubMed Web of Science ®Google Scholar
• Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10:1585–1605.
   PubMed Web of Science ®Google Scholar
• Rangel EB, Melaragno CS, de Sa JR, et al. Risk factors for the development of posttransplantation diabetes mellitus in simultaneous pancreas and kidney recipients. Transplant Proc. 2004;36:982–983.
   PubMed Web of Science ®Google Scholar
• Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14:1992–2000.
   PubMed Web of Science ®Google Scholar
• Porrini EL, Diaz JM, Moreso F, et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2016;31:495–505.
   PubMed Web of Science ®Google Scholar
• Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007;21:136–143.
   PubMed Web of Science ®Google Scholar
• Armstrong KA, Campbell SB, Hawley CM, et al. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant. 2005;5:2710–2718.
   PubMed Web of Science ®Google Scholar
• Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int. 2009;22:519–530.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185.
   PubMed Web of Science ®Google Scholar
• Cosio FG, Kudva Y, Van Der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67:2415–2421.
   PubMed Web of Science ®Google Scholar
• Chakkera HA, Weil EJ, Pham PT, et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36:1406–1412.
   PubMed Web of Science ®Google Scholar
• Hamer RA, Chow CL, Ong AC, et al. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation. 2007;83:36–40.
   PubMed Web of Science ®Google Scholar
• Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant. 2010;10:398–406.
   PubMed Web of Science ®Google Scholar
• Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, et al. The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis. Can J Diabetes. 2016;40:521–528.
   PubMed Web of Science ®Google Scholar
• Cheungpasitporn W, Thongprayoon C, Harindhanavudhi T, et al. Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis. Endocr Res. 2016;41:142–147.
   PubMed Web of Science ®Google Scholar
• Rangel EB, Melaragno CS, Neves MD, et al. Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant. Exp Clin Transplant. 2010;8:29–37.
   PubMed Web of Science ®Google Scholar
• Langsford D, Dwyer K. Dysglycemia after renal transplantation: definition, pathogenesis, outcomes and implications for management. World J Diabetes. 2015;6:1132–1151.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Claes K, Bammens B, et al. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant. 2008;23:2033–2042.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–1514.
   PubMed Web of Science ®Google Scholar
• Van Duijnhoven EM, Christiaans MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol. 2002;13:213–220.
   PubMed Web of Science ®Google Scholar
• Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–983.
   PubMed Web of Science ®Google Scholar
• Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233–3239.
   PubMed Web of Science ®Google Scholar
• Oberholzer J, Thielke J, Hatipoglu B, et al. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc. 2005;37:999–1000.
   PubMed Web of Science ®Google Scholar
• KDIGO. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.
   PubMed Web of Science ®Google Scholar
• Fernandes-Silva G, de Ivani PM, Rangel EB. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2017;13:367-385.
   PubMed Web of Science ®Google Scholar
• Pirsch JD, Henning AK, First MR, et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. Am J Transplant. 2015;15:1982–1990.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274–282.
   PubMed Web of Science ®Google Scholar
• Jehle PM. Steroid-induced osteoporosis: how can it be avoided? Nephrol Dial Transplant. 2003;18:861–864.
   PubMed Web of Science ®Google Scholar
• Nouwen EJ, Dauwe S, Van Der Biest I, et al. Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int. 1993;44:147–158.
   PubMed Web of Science ®Google Scholar
• Gregorini M, Sileno G, Pattonieri EF, et al. Understanding bone damage after kidney transplantation: a retrospective monocentric cross sectional analysis. Transplant Proc. 2017;49:650–657.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.
   PubMed Web of Science ®Google Scholar
• Wong H-S, Chau K-F, Wong K-M, et al. Prevalence of osteoporosis in patients after renal transplantation: results from a single center. Hong Kong J Nephrol. 2005;7:70–76.
   Google Scholar
• Rangel EB, Sa JR, Gomes SA, et al. Charcot neuroarthropathy after simultaneous pancreas-kidney transplant. Transplantation. 2012;94:642–645.
   PubMed Web of Science ®Google Scholar
• Nikkel LE, Mohan S, Zhang A, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant. 2012;12:649–659.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45:638–649.
   PubMed Web of Science ®Google Scholar
• Fan SL, Almond MK, Ball E, et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;57:684–690.
   PubMed Web of Science ®Google Scholar
• Roe SD, Porter CJ, Godber IM, et al. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int. 2005;16:142–148.
   PubMed Web of Science ®Google Scholar
• Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World J Transplant. 2015;5:183–195.
   PubMedGoogle Scholar
• Boots JM, Christiaans MH, Van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs. 2004;64:2047–2073.
   PubMed Web of Science ®Google Scholar
• Boots JM, Van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221–227.
   PubMed Web of Science ®Google Scholar
• Secchi A, Malaise J, Caldara R. Metabolic results 3 years after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant. 2005;20(Suppl 2):ii18–24, ii62.
   PubMedGoogle Scholar
• Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int. 2010;23:1191–1204.
   PubMed Web of Science ®Google Scholar
• Popovtzer MM, Pinnggera W, Katz FH, et al. Variations in arterial blood pressure after kidney transplantation. Relation to renal function, plasma renin activity, and the dose of prednisone. Circulation. 1973;47:1297–1305.
   PubMed Web of Science ®Google Scholar
• Shimmyo A, Miyazaki S, Onoe S, et al. [Ocular complications after renal transplantation]. Nippon Ganka Gakkai Zasshi. 1997;101:220–226.
   PubMedGoogle Scholar
• Pai RP, Mitchell P, Chow VC, et al. Posttransplant cataract: lessons from kidney-pancreas transplantation. Transplantation. 2000;69:1108–1114.
   PubMed Web of Science ®Google Scholar
• James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23:403–420.
   PubMed Web of Science ®Google Scholar
• Tsampalieros A, Knoll GA, Molnar AO, et al. Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis. Transplantation. 2017;101:694–703.
   PubMed Web of Science ®Google Scholar
• Weaver DJ Jr., Selewski D, Janjua H, et al. Improved cardiovascular risk factors in pediatric renal transplant recipients on steroid avoidance immunosuppression: a study of the Midwest Pediatric Nephrology Consortium. Pediatr Transpl. 2016;20:59–67.
   PubMed Web of Science ®Google Scholar
• Hocker B, Weber LT, Feneberg R, et al. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant. 2010;25:617–624.
   PubMed Web of Science ®Google Scholar
• Maduram A, John E, Hidalgo G, et al. Metabolic syndrome in pediatric renal transplant recipients: comparing early discontinuation of steroids vs steroid group. Pediatr Transpl. 2010;14:351–357.
   PubMed Web of Science ®Google Scholar
• Ritchie AG, Clayton PA, McDonald SP, et al. Age-specific risk of renal graft loss from late acute rejection or non-compliance in the adolescent and young adult period. Nephrology (Carlton). 2018;23:585–591.
   PubMed Web of Science ®Google Scholar
• Leeaphorn N, Garg N, Khankin EV, et al. Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transpl Int. 2018;31:175–186.
   PubMed Web of Science ®Google Scholar
• Pascual J, Zamora J, Galeano C, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2009;1:CD005632.
   PubMed Web of Science ®Google Scholar
• Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation. 2004;78:1548–1556.
   PubMed Web of Science ®Google Scholar
• Pascual J, Galeano C, Royuela A, et al. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation. 2010;90:343–349.
   PubMed Web of Science ®Google Scholar
• Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010;89:1–14.
   PubMed Web of Science ®Google Scholar
• Pascual J, Royuela A, Galeano C, et al. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825–832.
   PubMed Web of Science ®Google Scholar
• Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–577.
   PubMed Web of Science ®Google Scholar
• Hruba P, Tycova I, Krepsova E, et al. Steroid free immunosuppression is associated with enhanced Th1 transcripts in kidney transplantation. Transpl Immunol. 2017;42:18–23.
   PubMed Web of Science ®Google Scholar
• Haller MC, Kammer M, Kainz A, et al. Steroid withdrawal after renal transplantation: a retrospective cohort study. BMC Med. 2017;15:8.
   PubMed Web of Science ®Google Scholar
• Monfa E, San SD, San Millan JCR, et al. Intermediate steroid withdrawal after renal transplantation and anti-HLA antibodies (HLA-Abs) development. Nefrologia. 2017;37:415–422.
   PubMed Web of Science ®Google Scholar
• Rama I, Cruzado JM, Gil-Vernet S, et al. Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation. 2005;80:164–168.
   PubMed Web of Science ®Google Scholar
• Ali AK, Guo J, Ahn H, et al. outcomes of late corticosteroid withdrawal after renal transplantation in patients exposed to tacrolimus and/or mycophenolate mofetil: meta-analysis of randomized controlled trials. Int J Organ Transplant Med. 2011;2:149–159.
   PubMedGoogle Scholar
• Laouad I, Halimi JM, Buchler M, et al. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. Transplantation. 2005;80:872–874.
   PubMed Web of Science ®Google Scholar
• Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388:3006–3016.
   PubMed Web of Science ®Google Scholar
• Sureshkumar KK, Marcus RJ, Chopra B. Role of steroid maintenance in sensitized kidney transplant recipients. World J Transplant. 2015;5:102–109.
   PubMedGoogle Scholar
• Opelz G, Dohler B. Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant. 2013;13:2096–2105.
   PubMed Web of Science ®Google Scholar
• Taber DJ, Hunt KJ, Gebregziabher M, et al. A comparative effectiveness analysis of early steroid withdrawal in black kidney transplant recipients. Clin J Am Soc Nephrol. 2017;12:131–139.
   PubMed Web of Science ®Google Scholar
• Haller MC, Royuela A, Nagler EV, et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2016;8:CD005632.
   PubMed Web of Science ®Google Scholar
• Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation. 2001;72:13–21.
   PubMed Web of Science ®Google Scholar
• Knight SR, Morris PJ. Steroid sparing protocols following nonrenal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl Int. 2011;24:1198–1207.
   PubMed Web of Science ®Google Scholar
• Montero N, Webster AC, Royuela A, et al. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;9:CD007669.
   PubMed Web of Science ®Google Scholar
• Villikka K, Varis T, Backman JT, et al. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol. 2001;57:457–460.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060–1067.
   PubMed Web of Science ®Google Scholar
• Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol. 2011;33:157–167.
   PubMed Web of Science ®Google Scholar
• Miozzari M, Ambuhl PM. Steroid withdrawal after long-term medication for immunosuppressive therapy in renal transplant patients: adrenal response and clinical implications. Nephrol Dial Transplant. 2004;19:2615–2621.
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18:2409–2414.
   PubMed Web of Science ®Google Scholar
• Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8:1531–1548.
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Ferron GM, Mis SM, et al. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol. 1996;36:1100–1106.
   PubMed Web of Science ®Google Scholar
• Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. Nephron. 1977;18:208–211.
   PubMed Web of Science ®Google Scholar
• Frey FJ, Gambertoglio JG, Frey BM, et al. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Eur J Clin Pharmacol. 1982;23:65–74.
   PubMedGoogle Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61:246–255.
   PubMed Web of Science ®Google Scholar
• Wassner SJ, Malekzadeh MH, Pennisi AJ, et al. Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol. 1977;8:293–297.
   PubMed Web of Science ®Google Scholar
• Frey FJ. Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients. Kidney Int. 1991;39:1034–1050.
   PubMed Web of Science ®Google Scholar
• Slayter KL, Ludwig EA, Lew KH, et al. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996;59:312–321.
   PubMed Web of Science ®Google Scholar
• Imani S, Jusko WJ, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Pediatr Transpl. 1999;3:126–130.
   PubMedGoogle Scholar
• McDonald SP, Russ GR. Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney Int. 2002;61:2259–2265.
   PubMed Web of Science ®Google Scholar
• Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96:e7151.
   PubMed Web of Science ®Google Scholar
• Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85:353–358.
   PubMed Web of Science ®Google Scholar
• Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006;6:842–846.
   PubMed Web of Science ®Google Scholar
• Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int. 2005;18:483–486.
   PubMed Web of Science ®Google Scholar
• Lane JT, Odegaard DE, Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92:e56–e57.
   PubMed Web of Science ®Google Scholar
• Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14:979–984.
   PubMedGoogle Scholar
• Alnasrallah B, Pilmore H, Manley P. Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. BMJ Open. 2017;7:e016813.
   PubMed Web of Science ®Google Scholar
• Larsen JL. Potential risks of metformin in transplant patients. Am J Transplant. 2012;12:795.
   PubMed Web of Science ®Google Scholar
• Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23:739–749.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016.
   Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Quteineh L, Bochud PY, Golshayan D, et al. CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. Pharmacogenom J. 2017;17:69–75.
   PubMed Web of Science ®Google Scholar
• Cen C, Fang HX, Yu SF, et al. Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation. Hepatobiliary Pancreat Dis Int. 2017;16:602–609.
   PubMed Web of Science ®Google Scholar
• Yalin GY, Akgul S, Tanrikulu S, et al. Evaluation of glutathione peroxidase and KCNJ11 gene polymorphisms in patients with new onset diabetes mellitus after renal transplantation. Exp Clin Endocrinol Diabetes. 2017;125:408–413.
   PubMed Web of Science ®Google Scholar
• Ong S, Kang SW, Kim YH, et al. Matrix metalloproteinase gene polymorphisms and new-onset diabetes after kidney transplantation in korean renal transplant subjects. Transplant Proc. 2016;48:858–863.
   PubMed Web of Science ®Google Scholar
• Cruzado JM, Moreno P, Torregrosa JV, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27:2487–2494.
   PubMed Web of Science ®Google Scholar